文献速递抗栓抗凝管理药物不良反应与药物警戒

口服抗血栓药物当代应用:聚焦双联与三联治疗

Contemporary Use of Oral Antithrombotic Agents: Focus on Dual and Triple Therapeutic Approaches.
PubMed 文献 · Pharmacotherapy · 2017-11-21

本综述讨论双联或三联抗血栓治疗在血栓性疾病中的应用,评估相关研究及国家指南与共识推荐,并就动脉粥样硬化性心血管疾病(ASCVD)患者的管理提供实践考虑。

要点

  • 抗血小板或抗凝药可降低血栓风险,部分适应证需联合治疗。
  • 联合治疗需个体化平衡血栓与出血风险。
  • ASCVD患者需双联抗血小板联合抗凝时决策常不明确。

核心结论

  • 抗血栓联合治疗需根据个体化血栓与出血风险进行平衡。

研究设计与样本

  • 综述,讨论双联或三联抗血栓治疗在血栓性疾病中的应用,并评估相关研究及国家指南与共识推荐。

主要发现

  • 抗血小板或抗凝药物可降低血栓风险,但部分适应证需联合治疗。
  • 联合治疗在降低血栓并发症的同时需考虑安全性。
  • ASCVD患者需双联抗血小板联合抗凝时,联合治疗的角色常不明确。

临床怎么用

  • 使用联合抗血栓策略时,临床医生应有效平衡个体化血栓与出血风险。
  • 针对ASCVD患者的管理可参考本综述提供的实践考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Atherosclerotic cardiovascular disease (ASCVD) represents a long-standing health care burden in most industrialized countries. Management of ASCVD is multifaceted, and utilization of antithrombotic agents is a key component of care to reduce vascular events. Minimizing thrombotic risk can be accomplished via antiplatelet or anticoagulant drugs; however, combination therapy is warranted for some indications. Although reducing thrombotic complications is important, it is equally vital to consider the safety of combination regimens. Thus clinicians must effectively balance both individualized thrombotic and bleeding risks when using this strategy. Scenarios occur in practice when determining the role for combination therapy is not clear, especially for patients with ASCVD who require both dual antiplatelet therapy plus anticoagulation. The aim of this review is to discuss the role of dual or triple antithrombotic therapies across the spectrum of thrombotic disease states. In addition to critiquing relevant research studies and evaluating key recommendations from nationally published guidelines and consensus statements involving the use of these agents, we offer practical considerations that can be utilized when managing patients with ASCVD.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Jenkins AT, Kantorovich A, Burman L, et al. Contemporary Use of Oral Antithrombotic Agents: Focus on Dual and Triple Therapeutic Approaches. Pharmacotherapy. 2017. PMID: 28981961. doi:10.1002/phar.2041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。